Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 52

Sort by

Sort Order Select

Journal Articles

Telomere Length and CD49d Cooperate with IGHV Gene Status As Predictors of Long-Term Progression-Free Survival in CLL Patients Treated with FCR-Based Regimens

Andrea GS Pepper, PhD, Antonella Zucchetto, PhD, Kevin Norris, PhD, Erika Tissino, PhD, Jerry Polesel, Zarni Soe, David Allsup, Anna Hockaday, Pei Loo Ow, Peter Hillmen, MBChB, PhD, Andrew Rawstron, PhD, Daniel Catovsky, MD FRCP, Riccardo Bomben, PhD, Duncan M Baird, PhD, Christopher Fegan, Valter Gattei, MD, Chris Pepper, BSc, PhD

Blood (2020) 136 (Supplement 1): 46–47.

https://doi.org/10.1182/blood-2020-141279

Published: 2020

Journal Articles

Ibrutinib and Obinutuzumab in CLL: MRD Responses Sustained for Several Years with Deepest MRD Depletion in Patients with >1 Year Prior Ibrutinib Exposure

Andy C. Rawstron, PhD, Peter Hillmen, MBChB, FRCP, FRCPath, PhD, Shanna Maycock, BSc, MSc, Nichola Webster, Kristian Brock, PhD, Rebecca H. Boucher, BSc, MSc, PhD, Francesca Yates, PhD, Rebecca Jarvis, BSc, Surita Dalal, PhD, Ruth M. de Tute, PhD FRCPath, Paul Moss, MBBS, PhD FRCP, Donald Macdonald, MBChB, MD FRCP, PhD FCRPath, Piers Patten, MD PhD, Christopher Fegan, Andrew Pettitt, MA, MB BChir, PhD MRCP, MRCPath, Christopher P. Fox, MD PhD, Adrian Bloor, PhD FRCP, FRCPath, Oonagh Sheehy, MB BCh BAO, MRCP, FRCPath, Peter Hillmen, MBChB, PhD

Blood (2020) 136 (Supplement 1): 27–28.

https://doi.org/10.1182/blood-2020-136990

Published: 2020

Journal Articles

A Phase 1b-2 Study of KRT-232, a First-in-Class, Oral, Small Molecule Inhibitor of Murine Double Minute 2 (MDM2), in Combination with Acalabrutinib for the Treatment of Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or R/R Diffuse Large B-Cell Lymphoma (DLBCL)

Peter Hillmen, MBChB, PhD FRCP, FRCPath, Hope Qamoos, CNP, Anne Uyei, MD, Wayne M. Rothbaum, Wojciech Jurczak, MD PhD, Catherine Thieblemont, MD PhD, John C. Byrd, MD

Blood (2020) 136 (Supplement 1): 23–24.

https://doi.org/10.1182/blood-2020-134901

Published: 2020

Journal Articles

Incomplete Complement Inhibition in Patients with PNH on Eculizumab - 5 Year Experience from the National PNH Service Leeds

Rachael Jones, BSc, Petra Muus, MD PhD, Talha Munir, MBBS, Alexandra Pike, MBBS, Louise Arnold, Jeanifer Gachev, Briony Forrest, Peter Hillmen, MBChB, PhD, Morag Griffin, MBChB, FRCPath

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-140256

Published: 2020

Journal Articles

Management of Meningococcal Disease Risk in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) on Complement Inhibitors: 18 Years' Experience from the UK National PNH Service in Leeds

Louise Arnold, Ray Borrow, PhD FRCPath, Kathryn Riley, Talha Munir, MBBS, Richard Kelly, BSc, MD, Rachael Jones, BSc, Jeanifer Gachev, Briony Forrest, Alexandra Pike, MBBS, Petra Muus, MD PhD, Peter Hillmen, MBChB, PhD, Morag Griffin, MBChB, FRCPath

Blood (2020) 136 (Supplement 1): 5–6.

https://doi.org/10.1182/blood-2020-141780

Published: 2020

Journal Articles

Continued Long Term Responses to Ibrutinib + Venetoclax Treatment for Relapsed/Refractory CLL in the Blood Cancer UK TAP Clarity Trial

Blood (2020) 136 (Supplement 1): 17–18.

https://doi.org/10.1182/blood-2020-136960

Published: 2020

Journal Articles

Five-Year Analysis of Murano Study Demonstrates Enduring Undetectable Minimal Residual Disease (uMRD) in a Subset of Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Patients (Pts) Following Fixed-Duration Venetoclax-Rituximab (VenR) Therapy (Tx)

Blood (2020) 136 (Supplement 1): 19–21.

https://doi.org/10.1182/blood-2020-136109

Published: 2020

Journal Articles

Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naïve (TN) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with del(17p): Follow-up Results from Arm C of the SEQUOIA (BGB-3111-304) Trial

Blood (2020) 136 (Supplement 1): 11–12.

https://doi.org/10.1182/blood-2020-134280

Published: 2020

Journal Articles

Zanubrutinib in Combination with Venetoclax for Patients with Treatment-Naïve Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma and del(17p): Arm D of the SEQUOIA (BGB-3111-304) Trial

Constantine S. Tam, MBBS, MD, Ian W. Flinn, MD PhD, Alessandra Tedeschi, MD, Emmanuelle Ferrant, MD, Jennifer R. Brown, MD PhD, Tadeusz Robak, MDPhD, Paolo Ghia, MD PhD, Sowmya B. Kuwahara, PharmD, Jason C. Paik, MD PhD, Lei Hua, PhD, Aileen Cohen, MD PhD, Jane Huang, MD, Peter Hillmen, MBChB, PhD FRCP, FRCPath

Blood (2020) 136 (Supplement 1): 24–25.

https://doi.org/10.1182/blood-2020-134179

Published: 2020

Journal Articles

Results of the Pegasus Phase 3 Randomized Trial Demonstrating Superiority of the C3 Inhibitor, Pegcetacoplan, Compared to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria

Peter Hillmen, MBChB, PhD, Jeffrey Szer, MBBS, Ilene C. Weitz, Alexander Röth, MD, Britta Hoechsmann, Jens Panse, MD, Kensuke Usuki, MD PhD, Morag Griffin, MBChB, FRCPath, Jean-Jacques Kiladjian, MD PhD, Carlos M. de Castro, MD, Hisakazu Nishimori, MD PhD, Lisa Tan, Mohamed Hamdani, Pascal Deschatelets, PhD, Cedric Francois, MD PhD, Federico Grossi, MD, Antonio Risitano, Regis Peffault De Latour, MD PhD

Blood (2020) 136 (Supplement 1): 35–37.

https://doi.org/10.1182/blood-2020-142174

Published: 2020

Journal Articles

Pegcetacoplan Is Superior to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria Regardless of Prior Transfusion Requirement

Regis Peffault De Latour, MD PhD, Carlos M. de Castro, MD, Jeffrey Szer, MBBS, Kensuke Usuki, MD PhD, Peter Hillmen, MBChB, PhD, Morag Griffin, MBChB, FRCPath, Mohamed Hamdani, MS, Temitayo Ajayi, Hisakazu Nishimori, MD PhD, Ilene C. Weitz

Blood (2020) 136 (Supplement 1): 32–33.

https://doi.org/10.1182/blood-2020-141061

Published: 2020

Journal Articles

Thrombotic Events with Neisseria Meningitidis Vaccination in Patients with Paroxysmal Nocturnal Hemoglobinuria, UK Experience

Louise Arnold, Richard Kelly, BSc, MD, Talha Munir, MBBS, Petra Muus, MD PhD, Alexandra Pike, MBBS, Kathryn Riley, Briony Forrest, Jeanifer Gachev, Morag Griffin, MBChB, FRCPath, Peter Hillmen, MBChB, PhD

Blood (2020) 136 (Supplement 1): 35–36.

https://doi.org/10.1182/blood-2020-141769

Published: 2020

Journal Articles

Pooled Analysis of Cardiovascular Events from Clinical Trials Evaluating Acalabrutinib Monotherapy in Patients with Chronic Lymphocytic Leukemia (CLL)

Jennifer R Brown, MD PhD, John C. Byrd, MD, Paolo Ghia, MD PhD, Jeff P Sharman, MD, Peter Hillmen, MBChB, PhD FRCP, FRCPath, Deborah M. Stephens, DO, Clare Sun, MD, Wojciech Jurczak, John M. Pagel, MDPhD, Alessandra Ferrajoli, MD, Priti Patel, MD, Marshall Baek, Tamara Lezhava, Nataliya Kuptsova-Clarkson, MD, Javid J. Moslehi, MD, Richard R. Furman, MD

Blood (2020) 136 (Supplement 1): 52–54.

https://doi.org/10.1182/blood-2020-134797

Published: 2020

Journal Articles

Recurrent Gene Mutations and Clinical Outcome in the Context of Lenalidomide Treatment of Relapsed/Refractory CLL — Results from Multicenter Phase II Trial CLL-009

Veronika Opatrna, MD, Eugen Tausch, MD, Graeme Fraser, MD, Anne-Sophie Michallet, MD PhD, Peter Hillmen, MBChB, PhD, Jan Dürig, MD, Matt Kalaycio, MD, John G. Gribben, MDDSc FMedSci, Thomas J. Kipps, MD, Brendan Purse, Jennie Zhang, Sabine De Bedout, Asher A. Chanan-Khan, MD, Michael J. Hallek, MD, Clemens-Martin Wendtner, MD, Hartmut Döhner, MD, Stephan Stilgenbauer, MD PhD

Blood (2017) 130 (Supplement 1): 4311.

https://doi.org/10.1182/blood.V130.Suppl_1.4311.4311

Published: 2017

Journal Articles

Initial Results of Ibrutinib Plus Venetoclax in Relapsed, Refractory CLL (Bloodwise TAP CLARITY Study): High Rates of Overall Response, Complete Remission and MRD Eradication after 6 Months of Combination Therapy

Peter Hillmen, MBChB, PhD, Talha Munir, Andy Rawstron, PhD, Kristian Brock, MSc, BSc, Samuel Munoz Vicente, MSc, Francesca Yates, PhD, Rebecca Bishop, BSc, Christopher Fegan, MD, Donald Macdonald, Alison McCaig, PhD, Anna Schuh, MD PhD, Andrew Pettitt, FRCPath, PhD, John G. Gribben, MDDSc FMedSci, Stephen Devereux, FRCP, FRCPath, PhD, Adrian Bloor, Christopher P Fox, MBChB PhD, Francesco Forconi, MD DM, PhD FRCPath

Blood (2017) 130 (Supplement 1): 428.

https://doi.org/10.1182/blood.V130.Suppl_1.428.428

Published: 2017

Journal Articles

Pooled Analysis of Safety Data from Clinical Trials Evaluating Acalabrutinib Monotherapy in Hematologic Malignancies

John C. Byrd, MD, Roger Owen, MD, Susan M. O'Brien, MD, Jennifer R. Brown, MD PhD, Peter Hillmen, MBChB, PhD, Bojena Bitman, Nataliya Chernyukhin, MD, Ahmed Hamdy, MD, Raquel Izumi, PhD, Priti Patel, MD, Liat Schwartz-Sagi, MD, Edwin Tucker, MD, Nathan H. Fowler, MD, Matthew J. Streetly, BMBS, PhD MRCP, FRCPath, Adrian Wiestner, MD, Simon Rule, MD, Michael Wang, BS

Blood (2017) 130 (Supplement 1): 4326.

https://doi.org/10.1182/blood.V130.Suppl_1.4326.4326

Published: 2017

Journal Articles

Risk Factors for Grade 3/4 Transaminase Elevation in Patients with Chronic Lymphocytic Leukemia Treated with Idelalisib

Jennifer R. Brown, MD PhD, Andrew D. Zelenetz, MD PhD, Richard R. Furman, MD, Nicole Lamanna, MD, Anthony R. Mato, MD, Marco Montillo, MD, Susan M. O'Brien, MD, Lyndah K. Dreiling, MD, Ronald L. Dubowy, MD, Yeonhee Kim, PhD, Veerendra B. Munugalavada, PhD, Tadeusz Robak, MD PhD, Peter Hillmen, MBChB, PhD

Blood (2017) 130 (Supplement 1): 3016.

https://doi.org/10.1182/blood.V130.Suppl_1.3016.3016

Published: 2017

Journal Articles

BCR Unresponsiveness and 13q14 Duplication Underpin Spontaneous Disease Regression in Chronic Lymphocytic Leukemia

Blood (2017) 130 (Supplement 1): 3004.

https://doi.org/10.1182/blood.V130.Suppl_1.3004.3004

Published: 2017

Journal Articles

Obinutuzumab As Consolidation after Chemo-Immunotherapy Is Highly Effective in Achieving MRD Clearance from Bone Marrow and Peripheral Blood- Initial Results of UK NCRI Phase II/III Galactic Trial

Talha Munir, Peter Hillmen, MBChB, PhD, Lucy McParland, Dena Cohen, Anna Hockaday, Jamie Oughton, Fabrizio Messina, David Phillips, Jeffrey R. Neilson, FRCP,FRCPath, Nicholas Pemberton, Shankara Paneesha, MD MRCP, FRCPath, Ben Kennedy, MBChB, FRCP, FRCPath, Andy Rawstron, PhD

Blood (2017) 130 (Supplement 1): 3013.

https://doi.org/10.1182/blood.V130.Suppl_1.3013.3013

Published: 2017

Journal Articles

The Bloodwise TAP Calibre Feasibility Study to Assess the Mechanism of Action of Idelalisib in B-Cell Receptor Pathway (BCR) Inhibition in Chronic Lymphocytic Leukaemia (CLL)

Talha Munir, Peter Hillmen, MBChB, PhD, Andy Rawstron, PhD, Kristian Brock, MSc, BSc, Samuel Munoz-Vicente, Francesca Yates, PhD, Surita Dalal, PhD, Ruth M de Tute, PhD FRCPath, Chris P Fox, Donald Macdonald, Christopher Fegan, MD, Adrian Bloor, Anna Schuh, MD PhD, Gina Doody

Blood (2017) 130 (Supplement 1): 3014.

https://doi.org/10.1182/blood.V130.Suppl_1.3014.3014

Published: 2017

NARROW

Telomere Length and CD49d Cooperate with IGHV Gene Status As Predictors of Long-Term Progression-Free Survival in CLL Patients Treated with FCR-Based Regimens

Ibrutinib and Obinutuzumab in CLL: MRD Responses Sustained for Several Years with Deepest MRD Depletion in Patients with >1 Year Prior Ibrutinib Exposure

A Phase 1b-2 Study of KRT-232, a First-in-Class, Oral, Small Molecule Inhibitor of Murine Double Minute 2 (MDM2), in Combination with Acalabrutinib for the Treatment of Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or R/R Diffuse Large B-Cell Lymphoma (DLBCL)

Incomplete Complement Inhibition in Patients with PNH on Eculizumab - 5 Year Experience from the National PNH Service Leeds

Management of Meningococcal Disease Risk in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) on Complement Inhibitors: 18 Years' Experience from the UK National PNH Service in Leeds

Continued Long Term Responses to Ibrutinib + Venetoclax Treatment for Relapsed/Refractory CLL in the Blood Cancer UK TAP Clarity Trial

Five-Year Analysis of Murano Study Demonstrates Enduring Undetectable Minimal Residual Disease (uMRD) in a Subset of Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Patients (Pts) Following Fixed-Duration Venetoclax-Rituximab (VenR) Therapy (Tx)

Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naïve (TN) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with del(17p): Follow-up Results from Arm C of the SEQUOIA (BGB-3111-304) Trial

Zanubrutinib in Combination with Venetoclax for Patients with Treatment-Naïve Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma and del(17p): Arm D of the SEQUOIA (BGB-3111-304) Trial

Results of the Pegasus Phase 3 Randomized Trial Demonstrating Superiority of the C3 Inhibitor, Pegcetacoplan, Compared to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria

Pegcetacoplan Is Superior to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria Regardless of Prior Transfusion Requirement

Thrombotic Events with Neisseria Meningitidis Vaccination in Patients with Paroxysmal Nocturnal Hemoglobinuria, UK Experience

Pooled Analysis of Cardiovascular Events from Clinical Trials Evaluating Acalabrutinib Monotherapy in Patients with Chronic Lymphocytic Leukemia (CLL)

Recurrent Gene Mutations and Clinical Outcome in the Context of Lenalidomide Treatment of Relapsed/Refractory CLL — Results from Multicenter Phase II Trial CLL-009

Initial Results of Ibrutinib Plus Venetoclax in Relapsed, Refractory CLL (Bloodwise TAP CLARITY Study): High Rates of Overall Response, Complete Remission and MRD Eradication after 6 Months of Combination Therapy

Pooled Analysis of Safety Data from Clinical Trials Evaluating Acalabrutinib Monotherapy in Hematologic Malignancies

Risk Factors for Grade 3/4 Transaminase Elevation in Patients with Chronic Lymphocytic Leukemia Treated with Idelalisib

BCR Unresponsiveness and 13q14 Duplication Underpin Spontaneous Disease Regression in Chronic Lymphocytic Leukemia

Obinutuzumab As Consolidation after Chemo-Immunotherapy Is Highly Effective in Achieving MRD Clearance from Bone Marrow and Peripheral Blood- Initial Results of UK NCRI Phase II/III Galactic Trial

The Bloodwise TAP Calibre Feasibility Study to Assess the Mechanism of Action of Idelalisib in B-Cell Receptor Pathway (BCR) Inhibition in Chronic Lymphocytic Leukaemia (CLL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only